# Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

> **NCT01562990** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 11 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab, CMC544, Gemcitabine and Oxaliplatine

## Key facts

- **NCT ID:** NCT01562990
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-08
- **Final completion:** 2016-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562990, "Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01562990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*